

Références de la Formation de Base ALTO « Pathologies associées à l'usage d'héroïne » (2017)

Mortalité et overdoses

Buster MC, van Brussel GH, van den Brink W. An increase in overdose mortality during the first 2 weeks after entering or re-entering methadone treatment in Amsterdam. *Addiction* 2002;97(8):993-1001.

www.ncbi.nlm.nih.gov/pubmed/12144602

Caplehorn JR, Dalton MS, Haldar F, Petrenas AM, Nisbet JG. Methadone maintenance and addicts' risk of fatal heroin overdose. *Subst Use Misuse* 1996;31(2):177-96.

www.ncbi.nlm.nih.gov/pubmed/8834006

Cornish R, Macleod J, Strang J, Vickerman P, Hickman M. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Database. *BMJ* 2010;341: c5475.

www.ncbi.nlm.nih.gov/pubmed/20978062

Coffin P, Sullivan SD. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. *Ann Intern Med* 2013;158 : 1-9.

www.ncbi.nlm.nih.gov/pubmed/23277895

Darke S, Ross J, Hall W. Overdose among heroin users in Sydney, Australia. Prevalence and correlates of non-fatal overdose. *Addiction* 1996, 91(3):405-11.

www.ncbi.nlm.nih.gov/pubmed/8867202

Merrall EL, Kariminia A, Binswanger IA, Hobbs MS, Farrell M et al. Meta-analysis of drug-related deaths soon after release from prison. *Addiction* 2010;105(9):1545-54.

www.ncbi.nlm.nih.gov/pubmed/20579009

Nambiar D, Agius PA, Stoové M, Hickman M, Dietze P. Mortality in the Melbourne injecting drug user cohort study (MIX). *Harm Reduction Journal* 2015;12 :55

www.ncbi.nlm.nih.gov/pubmed/26654430

Schwartz RP, Gryczynski J, O'Grady KE, Sharfstein JM, Warren G et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009. *Am J Public Health* 2013;103(5):917-22.

www.ncbi.nlm.nih.gov/pubmed/23488511

Van Ameijden EJ, Langendam MW, Coutinho RA. Dose-effect relationship between overdose mortality and prescribed methadone dosage in low-threshold maintenance programs. *Addict Behav* 1999;24(4):559-63.

www.ncbi.nlm.nih.gov/pubmed/10466851

Infections des tissus mous

Brett M, Hood J, Brazier JS, Duerden BI, Hahné SJ. Soft tissue infections caused by spore-forming bacteria in injecting drug users in the United Kingdom. *Epidemiol Infect* 2005;133:575–582.

www.ncbi.nlm.nih.gov/pubmed/16050501

Gonzales y Tucker RD, Frazee B. View from the front lines: an emergency medicine perspective on clostridial infections in injection drug users. *Anaerobe* 2014;30:108-15.

www.ncbi.nlm.nih.gov/pubmed/25230330

Lloyd-Smith E, Kerr T, Hogg R, Li K, Montaner JS et al. Prevalence and correlates of abscesses among a cohort of injection drug users. *Harm Reduct J* 2005;2(24)
www.ncbi.nlm.nih.gov/pubmed/16281979

Palmateer NE, Hope VD, Roy K, Marongiu A, White JM et al. Infections with spore-forming bacteria in persons who inject drugs, 2000-2009. *Emerg Infect Dis* 2013;19(1):29-34.
www.ncbi.nlm.nih.gov/pubmed/23260795

Hépatite C

Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: A systematic review and meta-analysis. *Clinical Infectious Diseases* 2013 ; 57(S2), S80–S89.
www.ncbi.nlm.nih.gov/pubmed/23884071

Bate JP, Colman AJ, Frost PJ, Shaw DR, Harley HA. High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C. *J Gastroenterol Hepatol* 2010 ;25(7):1276-80.
www.ncbi.nlm.nih.gov/pubmed/20594255

Beutels M, Van Damme P, Aelvoet W, Desmyer J, Dondeyne F et al. Prevalence of hepatitis A, B and C in the Flemish population. *Eur J Epidemiol* 1997;13(3):275-80.
www.ncbi.nlm.nih.gov/pubmed/9258525

Bruggmann P, Litwin AH. Models of care for the management of hepatitis C virus among people who inject drugs : one size does not fit all. *Clinical Infectious Diseases* 2013;57(S2):S56–S61.
www.ncbi.nlm.nih.gov/pubmed/23884067

Denis B, Dedobbeleer M, Collet T, Petit J, Jamouille M et al. High prevalence of hepatitis C virus infection in Belgian intravenous drug users and potential role of the « Cotton-filter » in transmission: the GEMT study. *Acta Gastroenterol Belg* 2000;113:147-53.
www.ncbi.nlm.nih.gov/pubmed/10925449

Doerrbecker J, Behrendt P, Mateu-Gelabert P, Ciesek S, Riebesehl N et al. Transmission of hepatitis C virus among people who inject drugs: viral stability and association with drug preparation equipment *J Infect Dis* 2013;207(2):281-7.
www.ncbi.nlm.nih.gov/pubmed/23129759

Grebely J, Genoway KA, Raffa JD, Dhadwal G, Rajan T et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. *Drug Alcohol Depend* 2008;93(1-2):141-7.
www.ncbi.nlm.nih.gov/pubmed/17997050

Grebely J, Robaey G, Bruggmann P, Aghemo A, Backmund M et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. *Int J Drug Policy* 2015;26(10):1028-38
www.ncbi.nlm.nih.gov/pubmed/26847504

Hagan H, Pouget E, Des Jarlais DC. A Systematic Review and Meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. *J Infect Dis* 2011;204:74-83.
www.ncbi.nlm.nih.gov/pubmed/21628661

Hézode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien D et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. *Hepatology* 2005;42(1):63-71.
www.ncbi.nlm.nih.gov/pubmed/15892090

Hézode C, Zafrani ES, Roudot-Thoraval F, Costentin C, Hessami A et al. Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. *Gastroenterology* 2008;134(2):432-9.
www.ncbi.nlm.nih.gov/pubmed/18242211

Ishida JH, Peters MG, Jin C, Louie K, Tan V et al. Influence of cannabis use on severity of hepatitis C disease. *Clin Gastroenterol Hepatol* 2008;6:69–75.
www.ncbi.nlm.nih.gov/pubmed/18166478

Jakobsen JC, Niessen EE, Feinberg J, Katakam KK, Fobian K et al. Direct-acting antivirals for chronic hepatitis C. *Cochrane Database of Systematic Reviews* 2017.
www.ncbi.nlm.nih.gov/pubmed/28585310

Litwin AH, Harris KA, Nahvi S, Zamor PJ, Soloway IJ et al. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. *J Subst Abuse Treat* 2009;37(1):32-40.
www.ncbi.nlm.nih.gov/pubmed/19038524

MacArthur GJ, Minozzi S, Martin N, Vickerman P, Deren S et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. *BMJ* 2012;345:e5945.
www.ncbi.nlm.nih.gov/pubmed/23038795

Matheï C, Bourgeois S, Blach S, Brixko C, Mulkay JP, Razavi H, Robaey G. Mitigating the burden of hepatitis C virus among people who inject drugs in Belgium. *Acta Gastroenterol Belg* 2016; 79(2) :227-32.
www.ncbi.nlm.nih.gov/pubmed/27382943

Matheï C, Shkedy Z, Denis B, Kabali C, Aerts M et al. Evidence for a substantial role of sharing or injecting paraphernalia others than syringes/needles to the spread of hepatitis C among injecting drug users. *J Viral Hepat* 2006;13(8):560-70.
www.ncbi.nlm.nih.gov/pubmed/16901287

Moussali J, Delaquaize H, Boubilley D, Lhomme JP, Merleau Ponty J et al. Factors to improve the management of hepatitis C in drug users: an observational study in an addiction centre. *Gastroenterol Res Pract* 2010: 261472.
www.ncbi.nlm.nih.gov/pubmed/20811482

Novick DM, Kreek MJ. Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. *Addiction* 2008;103(6): 905-18.
www.ncbi.nlm.nih.gov/pubmed/18422827

Only just the beginning of the end of hepatitis C. *Lancet* 2014; 383: 281 (Editorial)
www.ncbi.nlm.nih.gov/pubmed/24461110

Robaey G, Buntinx F, Bottieau E, Bourgeois S, Brenard R et al. Guidelines for the management of chronic hepatitis C in patients infected after substance use. *Acta Gastroenterol Belg* 2005;68(1):38-45.
www.ncbi.nlm.nih.gov/pubmed/15832586

Traitement de l'hépatite C. *Folia Pharmacotherapeutica* 2014;41(8) :68-9.
http://www.cbip.be/fofia_pdfs/FR/P41F09.pdf

Endocardites et Torsades de pointe

Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney MC. QTc interval screening in methadone treatment. *Ann Intern Med* 2009;150(6):387-95.

www.ncbi.nlm.nih.gov/pubmed/19153406

Moss R, Munt B. Injection drug use and right sided endocarditis. *Heart* 2003;89:577-81.

www.ncbi.nlm.nih.gov/pubmed/12695478

Pani PP, Trogu R, Maremmanni I, Pacini M. QTc interval screening for cardiac risk in methadone treatment of opioid dependence. *Cochrane Database of Systematic Reviews* 2013; 6: CD008939.

www.ncbi.nlm.nih.gov/pubmed/23787716

Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MC. QT-interval effects of methadone, levomethadyl and buprenorphine in a randomized trial. *Arch Intern Med* 2007;167(22):2469-75.

www.ncbi.nlm.nih.gov/pubmed/18071169

Problèmes dentaires

Graham CH, Meechan JG. Dental management of patients taking methadone. *Dent Update* 2005; 32(8):477-8,481-2,485.

www.ncbi.nlm.nih.gov/pubmed/16262036

Madinier I, Harrosch J, Dugourd J, Giraud-Morin C, Fosse T. The buccal-dental health of drug addicts treated in the University Hospital Center in Nice. *Presse Med* 2003;32(20):919-23

www.ncbi.nlm.nih.gov/pubmed/12876534

Cocaïne

Karila L, Petit A, Phan O, Reynaud M. Les troubles psychotiques induits par la cocaïne : une revue synthétique. *Rev Med Liège* 2010 ;65(11) :623-7.

www.ncbi.nlm.nih.gov/pubmed/21189528

Lypka MA, Urata MM. Images in clinical medicine. Cocaine-induced palatal perforation. *N Engl J Med* 2007;357(19) :1956.

www.ncbi.nlm.nih.gov/pubmed/17989388

Nawrot TS, Perez L, Künzli N, Munters E, Nemery B. Public health importance of triggers of myocardial infarction: a comparative risk assessment. *Lancet* 2011 ; 377(9767) :732-40.

www.ncbi.nlm.nih.gov/pubmed/21353301

Prise en charge des consommateurs de cocaïne. HAS, Recommandations de Bonne Pratique, 2010.

<http://www.has-sante.fr>

Cannabis et cancer du poumon

Aldington S, Harwood M, Cox B, Weatherall M, Beckert L et al. Cannabis use and risk of lung cancer: a case-control study. *Eur Respir J* 2008;31(2) :280-6.

<https://www.ncbi.nlm.nih.gov/pubmed/18238947>

Berthiller J, Straif K, Boniol M, Voirin N, Benhaim-Luzon V et al. Cannabis smoking and risk of lung cancer in men: a pooled analysis of three studies in Maghreb. *J Thorac Oncol* 2008;3(12) :1398-403.

<https://www.ncbi.nlm.nih.gov/pubmed/19057263>

Bouti K, Borki R, Fenane H, Harrak L. Cannabis smoking and risk of lung cancer. A Systematic Review And Meta-Analysis. *Int J Med Surg* 2014;1(2):3-9.

<http://www.mbmj.org/index.php/ijms/article/view/57>

Callaghan RC, Allebeck P, Sidorchuk A. Marijuana use and risk of lung cancer: a 40-year cohort study. *Cancer Causes Control* 2013;24(10):1811-20.

<https://www.ncbi.nlm.nih.gov/pubmed/23846283>

Hashibe M, Morgenstern H, Cui Y, Tashkin DP, Zhang ZF et al. Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. *Cancer Epidemiol Biomarkers Prev* 2006;15(10) :1829-34.

<https://www.ncbi.nlm.nih.gov/pubmed/17035389>

Mehra R, Moore BA, Crothers K, Tetrault J, Fiellin DA. The association between marijuana smoking and lung cancer: a systematic review. *Arch Intern Med* 2006;166(13) :1359-67.

<https://www.ncbi.nlm.nih.gov/pubmed/16832000>

Zhang LR, Morgenstern H, Greenland S, Chang SC, Lazarus P et al. Cannabis smoking and lung cancer risk: pooled analysis in the International Lung Cancer Consortium. *Int J Cancer* 2015;136(4):894-903.

<https://www.ncbi.nlm.nih.gov/pubmed/24947688>

Cannabis et psychose

Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the association between the level of cannabis use and risk of psychosis. *Schizophr Bull* 2016;42(5):1262-9

<https://www.ncbi.nlm.nih.gov/pubmed/26884547>

Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB et al. Cannabis use and risk of psychotic or affective mental health outcomes : a systematic review. *Lancet* 2007, 370 : 319-27

<https://www.ncbi.nlm.nih.gov/pubmed/17662880>

Divers

Busse F, Omidi L, Timper K, Leichtle A, Windgassen M et al. Lead poisoning due to adulterated marijuana. *New Engl J Med* 2008 ;358(15) :1641-2

<https://www.ncbi.nlm.nih.gov/pubmed/18403778>